AbbVie Inc. (ABBV) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
AbbVie Inc. (ABBV) Profile & Business Summary
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Key Information
| Ticker | ABBV |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.abbvie.com |
Market Trend Overview for ABBV
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-10-01 (ET)
As of 2026-10-01, ABBV is showing signs of slowing down. Over the longer term, the trend remains bullish.
ABBV last closed at 259.93. The price is about 0.6 ATR below its recent average price (263.72), and the market is currently in a trend that may be losing strength. Price at 259.93 is near minor support around 252.33. Momentum may slow, while light resistance sits near 264.25. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 251.53. If price falls below this area, the current structure would likely weaken further.
On 2026-10-01, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-09-09] Price moved quickly and looked strong, but participation was limited.
Recent price action continues to trend lower in a relatively orderly manner, with no clear signs of structural stabilization yet emerging.
There was no clear sign of meaningful positions being carried into the overnight session.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not deploy this setup because predictability is still too low, internal signals are not aligned strongly enough, and price is still close to a gamma transition zone. Predictability is 20%, agreement is 36%, and reversal risk is 28%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 50 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-10-01. The current price is 259.93, 0.92% above the estimated average cost of 257.56. An estimated 54.3% of recent positioning is below the current price, while 45.3% is above it. The peak-density price is 264.80. The largest concentrated cost region is 261.35 to 266.55 and contains 37.8% of the estimated distribution. The nearest region below the current price is 258.75 to 259.45. The nearest region above the current price is 260.25 to 261.15.
Short Interest & Covering Risk for ABBV
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 9%)
Structure Analysis
ABBV Short positioning is starting to look crowded. Current days to cover is 4.5 trading days, meaning short positions would unwind somewhat slower than average. Short covering could add extra momentum to price moves. No meaningful structural fragility is currently detected (Fragility Score 24/100, DTC percentile 88%) and liquidity contracting meaningfully (volume -23%). Positioning is historically elevated, although price and liquidity conditions do not yet confirm structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Average trading volume is weakening, indicating contracting liquidity. Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-09-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.